During the past decade, Sarah Cannon/Colorado Blood Cancer Institute conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarah Cannon/Colorado Blood Cancer Institute" #1 sponsor was "Allogene Therapeutics" with 2 trials, followed by "Cellectis S.A." with 1 trials sponsored, "Karyopharm Therapeutics Inc" with 1 trials sponsored, "Nurix Therapeutics, Inc." with 1 trials sponsored and "Rubius Therapeutics" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

According to Clinical.Site data, the most researched conditions in "Sarah Cannon/Colorado Blood Cancer Institute" are "Relapsed/Refractory Multiple Myeloma" (3 trials), "Acute Myeloid Leukemia" (1 trials), "Chronic Lymphocytic Leukemia (CLL)" (1 trials), "Diffuse Large B-cell Lymphoma (DLBCL)" (1 trials) and "Follicular Lymphoma (FL)" (1 trials). Many other conditions were trialed in "Sarah Cannon/Colorado Blood Cancer Institute" in a lesser frequency.

Most popular intervention types in "Sarah Cannon/Colorado Blood Cancer Institute" are "Drug" (6 trials), "Biological" (3 trials) and "Genetic" (2 trials). Other intervention types were less common.

The name of intervention was led by "ALLO-647" (2 trials), "Cyclophosphamide" (2 trials), "Fludarabine" (2 trials), "ALLO-605" (1 trials) and "ALLO-715" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sarah Cannon/Colorado Blood Cancer Institute" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Sarah Cannon/Colorado Blood Cancer Institute". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Sarah Cannon/Colorado Blood Cancer Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Sarah Cannon/Colorado Blood Cancer Institute, 6 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".